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Abstract
Background About 2-7% of familial cardiomyopathy cases
are caused by a mutation in the gene encoding cardiac
troponin I (TNNI3). The related clinical phenotype is
usually severe with early onset. Here we report on all
currently known mutations in the Dutch population and
compared these with those described in literature.
Methods TheTNNI3 gene was screened for mutations in all
coding exons and flanking intronic sequences in a large
cohort of cardiomyopathy patients. All Dutch index cases
carrying a TNNI3 mutation that are described in this study
underwent extensive cardiological evaluation and were
listed by their postal codes.
Results In 30 families, 14 different mutations were
identified. Three TNNI3 mutations were found relatively
frequently in both familial and non-familial cases of
hypertrophic cardiomyopathy (HCM) or restrictive car-
diomyopathy (RCM). Haplotype analysis showed that p.
Arg145Trp and p.Ser166Phe are founder mutations in the
Netherlands, while p.Glu209Ala is not. The majority of
Dutch TNNI3 mutations were associated with a HCM
phenotype. Mean age at diagnosis was 36.5 years. Muta-
tions causing RCM occurred less frequently, but were
identified in very young children with a poor prognosis.
Conclusion In line with previously published data, we
found TNNI3 mutations to be rare and associated with early
onset and severe clinical presentation.
Keywords TNNI3.Founder.HCM.RCM.DCM
Introduction
Inherited hypertrophic cardiomyopathy (HCM) is caused by
genetic mutations that affect the cardiac sarcomere in around
75–80% of cases and is transmitted in an autosomal dominant
way. Early disease onset (< 45 years of age), familial
occurrence and an asymmetrical left ventricular wall thickness
of more than 20 mm are globally accepted criteria for the
diagnosis of HCM. In patients fulfilling these criteria there is a
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of these mutations are found in only nine sarcomeric genes
which are investigated in most Dutch cardiogenetic centres.
The performance of the sarcomere highly depends on a
functioning sliding mechanism, explaining why the majority
of mutations are found in genes, such as the beta-myosin heavy
chain (MYH7) and myosin binding protein-C3 (MYBPC3)
gene, encoding proteins which are crucial for this function [1].
Cardiomyocyte contraction is dependent on local sarco-
meric calcium levels, which is regulated by the small
troponin complex, consisting of the three subunits troponin
I, C and T [2]. Troponin I (TNNI3) binds to the thin
filament of the sarcomere and prevents muscle contraction
by inhibiting the actomyosin activity of the myosin heavy
chain. This inhibitory effect is released by calcium binding
to troponin C. This triggers a series of events including an
altered interaction within the actin–troponin–tropomyosin
binding complex, displacement of the myosin head along
the thin filament and adenosine triphosphate (ATP) hydro-
lysis, resulting in force generation. Troponin I3 is exclu-
sively expressed in cardiac muscle and plays a central role
in modulating cardiac muscle contraction and relaxation in
response to changes in intracellular calcium.
The prevalence of mutations in TNNI3 is believed to
be <5% in different types of cardiomyopathies such as
hypertrophic (HCM), restrictive (RCM) and dilated
(DCM) cardiomyopathy [3]. Phenotypic manifestations
range from clinically mild to severe with poor prognosis
often caused by sudden cardiac death [3, 4]. In the
literature, the majority of mutations in TNNI3 are found
in patients with HCM (85%) and RCM (8%) [5, 6]a n d
rarely in DCM [7]. Interestingly, even within families,
manifestations of different types of cardiomyopathy can be
observed such as HCM and RCM that are caused by the
same genetic defect. Contrary to HCM, RCM is charac-
terised by restrictive filling and minimal or no left
ventricular hypertrophy [8]. The presence of cardiomyo-
cyte disarray in RCM, which is a histological hallmark of
HCM, indicates that different types of cardiomyopathy fall
within the same disease spectrum. Functional studies on
RCM-causing TNNI3 mutations demonstrated a much
higher increase in calcium sensitivity compared with
HCM-causing mutations, which resulted in a more exagger-
ated HCM-like phenotype. Recently, TNNI3 mutations were
also reported in autosomal dominant DCM [7]. Functional
assays showed that these DCM causing TNNI3 mutations
resulted in lower maximum ATPase rates and decreased
calcium sensitivity compared with HCM [7]. These findings
corroborate with previously described alterations in DCM
caused by a mutation in the thin filaments.
The majority of the TNNI3 mutations (85%) have been
identified in exon 7 and exon 8, encoding domains interacting
with cardiac actin (ACTC1) and cardiac troponin C (TNNC1)
([4]; Fig. 1). The positions of reported mutations in TNNI3
reveal the presence of important functional domains, such as
protein binding or regulatory domains [9], such as phosphor-
ylation sites in the N-terminal part of cardiac troponin [10].
Mutations in TNNI3 have been reported in 2–7% of
HCM cases [3, 11]. As literature data are often population
specific, we investigated the prevalence of TNNI3 muta-
tions within the Dutch cardiomyopathy population derived
from four cardiogenetic centres. Based on the literature, the
low frequency of TNNI3 cases might be explained by the
severe clinical outcome of certain mutations. The fact that
such rare mutations are still present in the population can be
explained by the incidence of recurrent mutations due to
mutational hot spots (codons with high mutation rate) or by
founder mutations. In this study we combined patients and
genetic data from four Dutch cardiogenetic centres, which
offer diagnostic genetic testing of the TNNI3 gene in the
entire country of the Netherlands.
Methods
Patient selection
FourClinicalGeneticsCentresintheNetherlands(Rotterdam,
Amsterdam, Maastricht and Groningen) offer genetic testing
of the TNNI3 gene. All index patients underwent cardiolog-
ical evaluation, consisting at least of a 12-lead ECG,
transthoracic echocardiography and analysis of the family
history. A total of 1040 index patients were included up to
2009. From Amsterdam we included 298 HCM patients,
from Maastricht 250 HCM and 4 RCM patients, from
Groningen 130 HCM and/or DCM patients and from
Rotterdam 358 HCM index patients.
The postal codes of index patients carrying a mutation in
TNNI3 were collected and converted into an overview of
the Dutch postal code areas, based on the so called PC2
codes (the first two numbers of the postal code). These
comprise 90 different Dutch regions, each containing on
average 180,000 inhabitants.
Genetic evaluation
Total genomic DNA of the 1040 index patients (and 10
unaffected control persons) was extracted from EDTA
(peripheral) blood samples according to standard proce-
dures. Polymerase chain reaction (PCR) amplification and
subsequent pre-screening using denaturing gradient gel
electrophoresis (DGGE) and/or sequence analysis of the
TNNI3 gene was performed using primers located in
flanking intronic sequences (available on request). Nomen-
clature for the description of the mutation is in accordance
with the Human Genome Variation Society (HGVS) using
Neth Heart J (2011) 19:344–351 345NM_000363.4 as the mRNA reference sequence. Micro-
satellite markers D19S402, D19S571, D19S921, D19S926,
D19S880, D19S891, D19S210 and D19S887 flanking the
TNNI3 gene were used for haplotype analysis (details about
primers, PCR condition and fragment length are available
upon request).
Results
The total number of patients with cardiomyopathy
screened in this study was 1040. Among these patients,
14 different mutations (30 families in total) were found
in TNNI3 indicating a mutation frequency of 3% in the
Netherlands. Mean age at diagnosis was 36.5 years
(3 months to 69 years, Table 1). All 14 mutations were
detected in exon 7 or 8, and some mutations were found
more frequently than others. Three of these mutations
occurred more than four times in the Netherlands (see also
Fig. 2 and Table 1); p.Arg145Trp (8 times), p.Ser166Phe
(4 times) and p.Glu209Ala (5 times).
The p.Arg145Trp is the most frequent TNNI3 mutation
in the Netherlands (27% of all TNNI3 mutations) and is
randomly distributed over the country (Fig. 2). To investi-
gate whether these families have a common ancestor, we
performed haplotype analysis using eight polymorphic
markers spanning the TNNI3 gene. Indeed, individuals
carrying the mutation p.Arg145Trp show a unique short
haplotype for markers D19S880, D19S891 and D19S210
within a region of 0.5 Mb (haplotype allele length
respectively 96 bp, 177 bp and 105 bp). Unaffected controls
or probands with another type of mutation lack this specific
haplotype. Families carrying the p.Arg145Trp mutation
mainly showed LVH and ECGs typical for HCM. Although
not all ECG data were available from all individuals for our
study (Table 1), it is interesting to see that all patients who
had a clinical diagnosis of HCM by echocardiography also
had ECG abnormalities. Most patients with a p.Arg145Trp
mutation showed LVH and clear clinical symptoms
between the age of 40 and 50 years. In three families
with this mutation, cases of sudden death had occurred:
in one family at age 41 (RCM, family W in Table 1)a n d
in the other family (HCM, family AE in Table 1)a ta g e5 0 .
In the third family (HCM, family AD in Table 1)t w o
persons died suddenly at ages 13 and 38 years respectively
(no material was available to confirm the presence of the
mutation), while in the same family the sister of the index
patient with the mutation appeared to be unaffected at the age
of 67. One proband (family Q) survived an out-of-hospital
cardiac arrest. Differences in clinical expression were also
observed in other families with the p.Arg145Trp mutation. It
is not known whether this difference in clinical expression,
ranging from verysevere tounaffected, is due toan additional
genetic mutation or environmental cause.
The p.Ser166Phe mutation was found in four index
patients, three patients were from the same region within
Fig. 1 Schematic representation of the TNNI3 gene, the
corresponding protein structure and the sites of interaction with
sarcomeric contractile proteins. Mutations identified in this study and
majority known from literature are indicated. Mutations identified in
RCM patients are indicated in red, mutations identified in HCM
patients are indicated in black and mutations identified in DCM
patients are indicated in blue. The (novel) RCM mutations found in
this study are indicated in bold red. Boxes indicate exons, thin
lines indicate introns and thick lines indicate interacting domains.
Phosphorylation sites are indicated by PP
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348 Neth Heart J (2011) 19:344–351the province of Limburg. This is suggestive for a founder
mutation and indeed, haplotype analysis showed that p.
Ser166Phe carrying individuals also have a unique short
haplotype for markers D19S880, D19S891 and D19S210
within a region of 0.5 Mb (haplotype allele length 100 bp,
187 bp and 99 bp, respectively). The amino acid Ser166 is
highly conserved and located within the troponin C binding
domain. In addition, Ser166 is known as one of the
phosphorylation sites within TNNI3, involved in binding
capacity to troponin C [12]. These observations and
results from literature [3, 11] indicate that this is a
pathogenic mutation. The time of disease onset also seems
to be in the 4th decade of life, similar to patients having
the p.Arg145Trp mutation.
The mutation p.Glu209Ala was found in five probands
and is present in two different restricted areas, Groningen
and Zeeland (Fig. 2). Interestingly, this mutation has not
been described in the literature before. Unfortunately, the
precise age of diagnosis is not known for all index patients,
but also seems to be around the 4th decade of life. In four
out of five patients haplotype analysis was performed and at
least three different haplotypes surrounding the mutation
were observed, indicating the presence of a recurring
mutation due to a hot-spot rather than the presence of a
founder mutation.
Three of four idiopathic RCM cases that carried a TNNI3
mutation were proven ‘de novo’ and already presented
during childhood (ranging from birth to age of 10 years).
RCM cases as indicated in Table 1 fulfilled RCM criteria
such as impaired ventricular filling, normal or reduced
diastolic filling, normal wall thickness and normal systolic
function [13]. A de novo splice site mutation was detected
in a young girl (age 6 months) with severe RCM, who died
at the age of 1 year. One RCM-causing mutation,
p.Arg145Trp, was not de novo. It was found in a
19 years-old index patient, and displayed clinical heteroge-
neity within the family (HCM and RCM) (family W,
Table 1). The p.Arg145Trp is a founder mutation, which is
found in our study mainly in combination with HCM.
Another novel RCM causing mutation p.Arg192Cys was
found in combination with p.Arg145Gln in a young girl at
age 9 years. The latter mutation was found in a mosaic
status, which means that the p.Arg145Gln is not present in
all cells (details not shown) and therefore p.Arg192Cys is
probably the causative mutation. Unfortunately, the parents
were not referred for genetic testing, so no definitive
conclusions can be made regarding the origin of these two
mutations.
Discussion
In this study we identified 14 different mutations in TNNI3,
of which some mutations were found more frequently than
others. A frequency of 3% TNNI3 mutation in Dutch
cardiomyopathy families (1040 index patients) is in line
with data from Mogensen et al. who studied 748 consec-
utive families. Most mutations in TNNI3 described up till
now are found in exon 7 and 8, with some of these
mutations found more frequently than others. Concordantly,
we also identified most mutations in these exons.
The mutation Arg145Trp has frequently been reported in
the literature and was also found in eight families in our
study. The p.Arg145Trp mutation was identified in different
regions of the Netherlands. In most families so far only the
index patient has been investigated. Haplotype analysis
showed in seven families (ten carriers in total) that the
mutation arose from a common ancestor (founder effect).
An explanation for the presence of founder mutations is that
some mutations are better tolerated than others. Indeed, in
the literature one large family (Arg145Trp) was described
with more than four gene carriers who showed late onset
and low-risk disease without progression during follow-up
over 3 years [14–16]. None of the family members in this
large family had any risk factors for sudden death. The
proband had the most prominent LVH associated with
outflow tract obstruction. Two other individuals fulfilled
criteria for familial HCM and had abnormal ECGs but
normal echocardiograms. Magnetic resonance imaging
(MRI) detected LVH in both individuals. However, our
study shows that two out of eight founder carriers have
disease onset at a young age (age of 19 (RCM) and one
even before age of 9). A family member of the 19-year-old
RCM patient died suddenly at age 41. The difference in
disease expression and disease onset for this founder
Fig. 2 Overview of the three most frequently occurring TNNI3
mutations per home-region. Each home-region contains on average
180,000 inhabitants
Neth Heart J (2011) 19:344–351 349mutation (even within one family, see for example family
AD in Table 1) might be explained by additional mutations
present in other known or unknown genes encoding for
sarcomeric, cytoskeleton or nuclear envelope proteins next
to the mutation found in TNNI3.
In addition to the Arg145Trp mutation, Arg145Gly
and Arg145Gln [17] mutations have been identified
affecting the same amino acid position. In one of our
patients (19 years old) with RCM we found the founder
p.Arg145Trp substitution, which was also reported for
two other cases of RCM, who surprisingly had a
relatively old age (67 and 70 years) at first presentation
[8]. Since different mutations affect the same codon, we
speculate that this codon 145 is also subject to a high
mutation rate, which can lead to new patients having
either RCM or HCM,
The mutation p.Ser166Phe was found four times and
previously reported in the literature [11, 14]. Haplotype
analysis indicated that the p.Ser166Phe is a founder
mutation in the Netherlands. Almost all affected carriers
in our study and those known from literature [11] have
obstructive HCM (in some cases myectomy was performed)
including asymmetrical septum hypertrophy and ECG
abnormalities. The mutation affects a PKA phosphorylation
site [12] and phosphorylation of this site influences the
interaction of troponin I with the calcium-binding site of
troponin C [9]. HCM-causing missense mutations within the
amphipathic alpha-helix of TNNI3, spanning amino acids
164 to 188 and probably involved in the binding to actin-
tropomyosin, cause an increased calcium sensitivity while
DCM-causing mutations cause a decreased sensitivity [7].
The p.Glu209Ala has never been reported before, but in
the Netherlands it has been found in five index patients so
far. According to genetic criteria, it would have been
labelled as an unclassified variant of unknown pathological
significance (UV). However, the fact that this recurrent
mutation has been detected multiple times independently in
different centres supports a pathogenic character. The
position of the amino acid (p.Glu209), residing one codon
from the C-terminus end, may indicate an important
biological function. Several experimental studies have
indicated that residues located within the C terminus of
troponin I are involved in interaction with the regulatory
domain (N-terminal domain) of troponin C [18]. The C-
terminus of troponin I is highly conserved among the
troponin isoforms and its binding to the N terminus of
troponin C, which contains the low affinity calcium-specific
site, indicates that it may be important for calcium-
dependent regulation of cardiac muscle contraction [19].
A relatively high incidence of de novo TNNI3 mutations
was detected in young children (especially in young females
with RCM (2 out of 4)). The absence of family history but
presence of RCM in an index patient is a strong indication
for diagnostic TNNI3 mutation detection. This is similar to
the results by Mogensen [3], who reported that 30% of
TNNI3 mutations in RCM are caused by a de novo mutation.
Until now, all mutations found in TNNI3 are missense
mutations (Fig. 1). A splice site mutation in TNNI3 causing
RCM has never been reported before and probably causes a
truncated protein with a severe dominant negative effect. So
the extreme severity of the disease in this family was
probably due to the underlying molecular effect.
Conclusion
TNNI3 mutations have been identified in 3% of the
Dutch cardiomyopathy patients, with a relatively high
amount of frequently occurring mutations. Different
mutations that occur at the same position can lead to
different forms of cardiomyopathy with variable pene-
trance. Our findings show that disease-causing mutations
can lead to either HCM, RCM or DCM (or a combina-
tion of both within families) depending on the specific
mutation. We hypothesise that the presence of RCM and
other cardiomyopathies within one family might still be
explained by additional mutations present in genes
encoding cytoskeleton or nuclear envelope proteins
additional to the TNNI3 mutation. Even in families with
ap r o v e n‘founder mutation’, the phenotypic heterogeneity
is remarkable, indicating that other genetic background
cannot be ruled out and might be explained by linked or
even unlinked genetic modifiers. In each case of RCM,
especially in young patients, TNNI3 analysis should still
be the initial gene to be excluded.
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